ISSN 0253-2778

CN 34-1054/N

Open AccessOpen Access JUSTC Original Paper

Research and development of biotechnology and drugs

Cite this:
  • Received Date: 28 June 2008
  • Rev Recd Date: 10 August 2008
  • Publish Date: 31 August 2008
  • As an example of R & D of Biotechnology and Drugs at USTC, several monoclonal antibodies (Abs) have been prepared for applications in industrial and medicinal applications. The Ab against human α-interferon (IFN) was used to prepare the IFN affinity chromatography gel which can provide efficient means for the manufacture of IFNs. It made this key technique for manufacturing IFNs no longer rely on input. Based on these, Anhui Anke High Biotechnology INC was founded in 1995. One of the Abs against oncoprotein p185erbB-2/HER-2 was developed for the diagnostic reagent of the cancers overexpressing oncoprotein p185 such as breast cancer and ovary cancer. This diagnostic reagent was proved by SFDA in 2004. Another Ab against p185 which can inhibit growth and proliferation of cancers overexpressing p185 is being developed into a therapeutic antibody drug. In addition, the fragments with anti-platelet aggregation activities have been developed for a potential anti-thrombus drug by a pharmaceutical company based on the research of the Labs in our school. More achievements are being made at USTC and will be applyied to biotech industries.
    As an example of R & D of Biotechnology and Drugs at USTC, several monoclonal antibodies (Abs) have been prepared for applications in industrial and medicinal applications. The Ab against human α-interferon (IFN) was used to prepare the IFN affinity chromatography gel which can provide efficient means for the manufacture of IFNs. It made this key technique for manufacturing IFNs no longer rely on input. Based on these, Anhui Anke High Biotechnology INC was founded in 1995. One of the Abs against oncoprotein p185erbB-2/HER-2 was developed for the diagnostic reagent of the cancers overexpressing oncoprotein p185 such as breast cancer and ovary cancer. This diagnostic reagent was proved by SFDA in 2004. Another Ab against p185 which can inhibit growth and proliferation of cancers overexpressing p185 is being developed into a therapeutic antibody drug. In addition, the fragments with anti-platelet aggregation activities have been developed for a potential anti-thrombus drug by a pharmaceutical company based on the research of the Labs in our school. More achievements are being made at USTC and will be applyied to biotech industries.
  • loading
  • [1]
    Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene[J]. Science, 1987,235:177-182.
    [2]
    Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science, 1989, 244:707-712.
    [3]
    Ross J S, Fletcher J A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy[J]. Stem Cell, 1998,16: 413-428.
    [4]
    Hynes N E, Stern D F. The biology of erbB-2/neu/HER-2 and its role in cancer[J]. Biochem Biophys Acta, 1994,1 198:165-184.
    [5]
    王琛,吴强,李昀,等. 表面表位包埋法制备肿瘤表面抗原p185nue/c-erbB-2单克隆抗体及其性质研究[J]. 中国免疫学杂志, 2000,16: 539-546.
    [6]
    Goldenberg M M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody: A novel agent for the treatment of metastatic breast cancer[J]. Clinical Therapeutics, 1999,21:309-318.
    [7]
    Gregory P Adams, Louis M Weiner. Monoclonal antibody therapy of cancer[J]. Nature Biotechnology,2005,23:1 117.
    [8]
    Cheng L, Liu A, Yang J, et al. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185c-erbB-2[J]. Cell Research, 2003,13: 35-48.
    [9]
    Hu S, Zhu Z, Li L, et al. Fine epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for anti-tumor mechanism[J]. Proteins, 2008,70:938-949.
  • 加载中

Catalog

    [1]
    Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene[J]. Science, 1987,235:177-182.
    [2]
    Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer[J]. Science, 1989, 244:707-712.
    [3]
    Ross J S, Fletcher J A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy[J]. Stem Cell, 1998,16: 413-428.
    [4]
    Hynes N E, Stern D F. The biology of erbB-2/neu/HER-2 and its role in cancer[J]. Biochem Biophys Acta, 1994,1 198:165-184.
    [5]
    王琛,吴强,李昀,等. 表面表位包埋法制备肿瘤表面抗原p185nue/c-erbB-2单克隆抗体及其性质研究[J]. 中国免疫学杂志, 2000,16: 539-546.
    [6]
    Goldenberg M M. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody: A novel agent for the treatment of metastatic breast cancer[J]. Clinical Therapeutics, 1999,21:309-318.
    [7]
    Gregory P Adams, Louis M Weiner. Monoclonal antibody therapy of cancer[J]. Nature Biotechnology,2005,23:1 117.
    [8]
    Cheng L, Liu A, Yang J, et al. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185c-erbB-2[J]. Cell Research, 2003,13: 35-48.
    [9]
    Hu S, Zhu Z, Li L, et al. Fine epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for anti-tumor mechanism[J]. Proteins, 2008,70:938-949.

    Article Metrics

    Article views (567) PDF downloads(192)
    Proportional views

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return